21-hydroxylase deficiency primary prevention: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(11 intermediate revisions by 5 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Congenital adrenal hyperplasia due to 21-hydroxylase deficiency}}
{{21-hydroxylase deficiency}}
Please help WikiDoc by adding more content here. It's easy!  Click  [[Help:How to Edit a Page|here]] to learn about editing.
{{CMG}}; {{AE}} {{MJ}}
== References ==
 
==Overview==
[[Pre-natal]] diagnosis of 21-hydroxylase deficiency is established to [[Prevention (medical)|prevent]] complications of the disease in future life and treated with [[pre-natal]] [[dexamethasone]].  
==Primary Prevention==
* [[Pre-natal]] diagnosis of 21-hydroxylase deficiency in patients with positive [[family history]] is established to prevent complications in future. A positive diagnosis is treated with [[prenatal]] [[dexamethasone]].
* The tests available for making a [[pre-natal]] diagnosis of 21-hydroxylase deficiency include:
** [[Amniotic fluid]] testing
** [[Oligonucleotide]] hybridization of [[deoxyribonucleic acid]] ([[DNA]]) obtained from [[chorionic villus sampling]] utilizes [[fetal]] [[DNA]] extracted from maternal blood through non-invasive methods.<ref name="pmid27378492">{{cite journal |vauthors=Kazmi D, Bailey J, Yau M, Abu-Amer W, Kumar A, Low M, Yuen T |title=New developments in prenatal diagnosis of congenital adrenal hyperplasia |journal=J. Steroid Biochem. Mol. Biol. |volume=165 |issue=Pt A |pages=121–123 |year=2017 |pmid=27378492 |doi=10.1016/j.jsbmb.2016.06.016 |url=}}</ref>
 
==References==
{{Reflist|2}}
{{Reflist|2}}
{{WikiDoc Help Menu}}
{{WH}}
{{WikiDoc Sources}}
{{WS}}
[[Category:Needs content]]
[[Category:Disease]]
[[Category:Disease]]
[[Category:Pediatrics]]
[[Category:Pediatrics]]
Line 12: Line 20:
[[Category:Genetic disorders]]
[[Category:Genetic disorders]]
[[Category:Intersexuality]]
[[Category:Intersexuality]]
[[Category:Medicine]]
[[Category:Up-To-Date]]​

Latest revision as of 15:29, 24 July 2020

Congenital adrenal hyperplasia main page

21-hydroxylase deficiency Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating 21-Hydroxylase Deficiency from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

21-hydroxylase deficiency primary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of 21-hydroxylase deficiency primary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on 21-hydroxylase deficiency primary prevention

CDC on 21-hydroxylase deficiency primary prevention

21-hydroxylase deficiency primary prevention in the news

Blogs on 21-hydroxylase deficiency primary prevention

Directions to Hospitals Treating 21-Hydroxylase Deficiency

Risk calculators and risk factors for 21-hydroxylase deficiency primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mehrian Jafarizade, M.D [2]

Overview

Pre-natal diagnosis of 21-hydroxylase deficiency is established to prevent complications of the disease in future life and treated with pre-natal dexamethasone.

Primary Prevention

References

  1. Kazmi D, Bailey J, Yau M, Abu-Amer W, Kumar A, Low M, Yuen T (2017). "New developments in prenatal diagnosis of congenital adrenal hyperplasia". J. Steroid Biochem. Mol. Biol. 165 (Pt A): 121–123. doi:10.1016/j.jsbmb.2016.06.016. PMID 27378492.

Template:WH Template:WS